A study has shown that the use of exhaled volatile organic compounds (VOCs) can be used as biomarkers for differentially identifying liver disease on breath.
The company reports it has met the enrollment target for a trial of its sonic beam therapy, one step closer to submitting for FDA approval of the product.
The digital pathology firm and image-analysis software developer will partner on artificial intelligence based solutions to improve trial decision making.
Conducted by SubjectWell, the survey of patients with Type 2 diabetes reveals how ethnicity and other factors play a part in trial participation tendencies.
BioIVT taps into the advantages of hepatic cells for toxicology evaluations and screening studies, securing exclusive distribution agreement with upcyte.
Sobi announces that it will acquire Dova, adding Doptelet to its portfolio of hemophilia treatments, as it looks to further expand indications and diversify its revenue base.
Researchers show miniature livers can develop steatohepatitis and fibrosis, pointing to potential for personalized hepatic drug discovery and toxicity platforms.
Aiming to speed up and facilitate the clinical development of liver failure treatments, Taconic launches the first commercially available diet-induced NASH rodent model.
The US FDA has warned that people with decreased liver function who taker higher than recommended doses of Intercept Pharma’s drug Ocaliva are at increased risk of liver injury and death.
An Israeli researcher says a cost-effective method for making human liver cells offers drug developers better safety evaluation and will “undoubtedly” replace animal testing.
Merck & Co. has struck a deal with Organovo to use a 3D printed human liver system for toxicology testing as a supplement to in vitro and preclinical animal testing.
Increasing the predictivity of in vitro systems could cut the costs of drug development and shift preclinical research away from animal models, according to Crown Bioscience.
A 3D printed human liver system could offer better informed risk-based decisions earlier in the drug development process than with current in vitro models, according to developers Organovo.
Disposable bioreactors could be the centerpiece of a project to develop and harvest large quantities of cells that eventually will be used in bioartificial livers for patients with severe liver failure.
Although it is widely acknowledged that medical bracelets can be the difference between life and death, Australia’s Nanotechnology Victoria (NanoVic) has become the first to take the idea further with its insulin-delivering jewellery project.
US-based Delcath Systems has achieved positive results in treating
diffuse liver cancer using its percutaneous hepatic perfusion (PHP)
delivery system.
French firm Diatos has created a second generation irinotecan
cancer therapy using its patented peptide-based drug delivery
system, coming up with a drug that has greatly improved efficacy
and safety profile compared to current irinotecan...
The search for better models to predict drug-induced human liver
damage has led the FDA (US Food and Drug Administration) to turn to
Entelos to design a 'virtual liver' to guide biomarker and assay
development.
A technology designed to preserve living cells for longer could
significantly reduce the number of animals used in medical
research, according to its creators Abcellute.
A cell preservation solution that makes research using kidney cells
easier to carry out, developed by UK firm Abcellute, has been made
available on the Japanese market. Abcellute licensed Japanese
rights to the product to GeneFrontier,...
Gentronix has been granted a research award, which is to fund a
potentially viable alternative to animal testing, reducing the need
for their use during drug development.
Coremed has introduced its proprietary drug-delivery platform
technology that improves absorption of certain proteins and
macromolecules such as insulin within the gastrointestinal tract.
Researchers have, for the first time, identified two separate
populations of immune cells in the liver, which will help doctors
understand the mechanisms by which the liver is damaged and
repaired and may lead to future drug therapies.
Drug discovery company Cambrex' intention to enter a key segment of
the drug discovery arena was substantiated by its purchase of
immortalised cell lines, related technology and equipment.
Bioengineers at the University of Oxford have developed a solution
to the problem of toxicity testing for new drugs, which can prove
to be ineffective or at worst dangerous to humans.
